Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 4/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PAM | P19021 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1563570 | 0.96 | HAO1 (0.48) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL10799382 | 0.95 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL1562098 | 0.95 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL1562138 | 0.95 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL10595444 | 0.95 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL29022869 | 0.95 | HAO1 (0.52) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL14604888 | 0.91 | HAO1 (0.41) | HAO1MAPTKMT2ADGKACES2 | |
| SCHEMBL10799584 | 0.85 | FAAH (0.55) | MAPTKMT2ALMNAFAAHPOLB | |
| SCHEMBL10799580 | 0.85 | FAAH (0.55) | MAPTKMT2ALMNAFAAHPOLB | |
| SCHEMBL6415291 | 0.83 | ALDH1A1 (0.41) | CES2CES1CTSKEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | HAO1 392/4885MAPT 4506/4885KMT2A 3563/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | HAO1 397/4885MAPT 4506/4885KMT2A 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.